Published in Mol Pharm on February 14, 2008
Systems pharmacology, pharmacogenetics, and clinical trial design in network medicine. Wiley Interdiscip Rev Syst Biol Med (2012) 0.97
Δ-9,11 modification of glucocorticoids dissociates nuclear factor-κB inhibitory efficacy from glucocorticoid response element-associated side effects. J Pharmacol Exp Ther (2012) 0.90
Translational biomarkers: from preclinical to clinical a report of 2009 AAPS/ACCP Biomarker Workshop. AAPS J (2011) 0.85
Comparative analysis of acute and chronic corticosteroid pharmacogenomic effects in rat liver: transcriptional dynamics and regulatory structures. BMC Bioinformatics (2010) 0.79
Inference of gene regulatory networks incorporating multi-source biological knowledge via a state space model with L1 regularization. PLoS One (2014) 0.79
Quantitative Systems Pharmacology: A Framework for Context. Curr Pharmacol Rep (2016) 0.76
Meta-modeling of methylprednisolone effects on glucose regulation in rats. PLoS One (2013) 0.75
Genomic data assimilation using a higher moment filtering technique for restoration of gene regulatory networks. BMC Syst Biol (2015) 0.75
Mechanisms involved in the side effects of glucocorticoids. Pharmacol Ther (2002) 5.43
Glucocorticoids activate the ATP-ubiquitin-dependent proteolytic system in skeletal muscle during fasting. Am J Physiol (1993) 2.33
Transdifferentiation of mouse aortic smooth muscle cells to a macrophage-like state after cholesterol loading. Proc Natl Acad Sci U S A (2003) 2.23
Influence of glucocorticoids and disease activity on total and high density lipoprotein cholesterol in patients with rheumatoid arthritis. Ann Rheum Dis (2003) 1.91
Modeling of corticosteroid pharmacogenomics in rat liver using gene microarrays. J Pharmacol Exp Ther (2003) 1.71
Suppressors of cytokine signaling-1 and -6 associate with and inhibit the insulin receptor. A potential mechanism for cytokine-mediated insulin resistance. J Biol Chem (2001) 1.67
Corticosteroid effects on cell signalling. Eur Respir J (2006) 1.63
The effect of insulin on expression of genes and biochemical pathways in human skeletal muscle. Endocrine (2007) 1.44
Fourth-generation model for corticosteroid pharmacodynamics: a model for methylprednisolone effects on receptor/gene-mediated glucocorticoid receptor down-regulation and tyrosine aminotransferase induction in rat liver. J Pharmacokinet Biopharm (1998) 1.43
Pharmacodynamics and pharmacogenomics of methylprednisolone during 7-day infusions in rats. J Pharmacol Exp Ther (2002) 1.36
Pharmacokinetic/Pharmacodynamic models for corticosteroid receptor down-regulation and glutamine synthetase induction in rat skeletal muscle by a Receptor/Gene-mediated mechanism. J Pharmacol Exp Ther (1999) 1.27
Glucocorticoid regulation of insulin receptor and substrate IRS-1 tyrosine phosphorylation in rat skeletal muscle in vivo. J Clin Invest (1993) 1.15
Corticosteroid-regulated genes in rat kidney: mining time series array data. Am J Physiol Endocrinol Metab (2005) 1.14
Regulation of mitochondrial sn-glycerol-3-phosphate acyltransferase activity: response to feeding status is unique in various rat tissues and is discordant with protein expression. Arch Biochem Biophys (2001) 1.14
Pharmacogenomic responses of rat liver to methylprednisolone: an approach to mining a rich microarray time series. AAPS J (2005) 1.11
Modeling circadian rhythms of glucocorticoid receptor and glutamine synthetase expression in rat skeletal muscle. Pharm Res (2006) 1.10
Elevated free fatty acids attenuate the insulin-induced suppression of PDK4 gene expression in human skeletal muscle: potential role of intramuscular long-chain acyl-coenzyme A. J Clin Endocrinol Metab (2007) 1.08
In vivo multi-tissue corticosteroid microarray time series available online at Public Expression Profile Resource (PEPR). Pharmacogenomics (2003) 1.06
The genomic response of skeletal muscle to methylprednisolone using microarrays: tailoring data mining to the structure of the pharmacogenomic time series. Pharmacogenomics (2004) 1.05
Mechanism of action of glucocorticosteroid hormones: possible implications for therapy of neuroimmunological disorders. J Neuroimmunol (2001) 1.02
Receptor/gene-mediated pharmacodynamic effects of methylprednisolone on phosphoenolpyruvate carboxykinase regulation in rat liver. J Pharmacol Exp Ther (2004) 1.02
Peroxisome proliferator-activated receptor (PPAR) gamma and retinoid X receptor (RXR) agonists have complementary effects on glucose and lipid metabolism in human skeletal muscle. Diabetologia (2001) 1.00
Temporal profiling of the transcriptional basis for the development of corticosteroid-induced insulin resistance in rat muscle. J Endocrinol (2005) 1.00
Corticosterone alters insulin signaling in chicken muscle and liver at different steps. J Endocrinol (1999) 0.82
Application of scaling factors in simultaneous modeling of microarray data from diverse chips. Pharm Res (2007) 0.80
Corticosterone inhibits the lipid-mobilizing effects of oleoyl-estrone in adrenalectomized rats. Endocrinology (2007) 0.80
[Effect of lipid infusion on the function of islet beta cells and gene expression of insulin signal transduction system]. Beijing Da Xue Xue Bao (2007) 0.77
Glucose restriction inhibits skeletal myoblast differentiation by activating SIRT1 through AMPK-mediated regulation of Nampt. Dev Cell (2008) 5.51
Genomics, intellectual disability, and autism. N Engl J Med (2012) 3.74
Elevated stearoyl-CoA desaturase-1 expression in skeletal muscle contributes to abnormal fatty acid partitioning in obese humans. Cell Metab (2005) 3.47
An interactive power analysis tool for microarray hypothesis testing and generation. Bioinformatics (2006) 2.62
Sources of variability and effect of experimental approach on expression profiling data interpretation. BMC Bioinformatics (2002) 2.31
Nuclear envelope dystrophies show a transcriptional fingerprint suggesting disruption of Rb-MyoD pathways in muscle regeneration. Brain (2006) 2.22
Preclinical drug trials in the mdx mouse: assessment of reliable and sensitive outcome measures. Muscle Nerve (2009) 2.19
Changes in ubiquitin proteasome pathway gene expression in skeletal muscle with exercise and statins. Arterioscler Thromb Vasc Biol (2005) 2.12
Osteopontin promotes fibrosis in dystrophic mouse muscle by modulating immune cell subsets and intramuscular TGF-beta. J Clin Invest (2009) 2.10
Gene profiling in spinal cord injury shows role of cell cycle in neuronal death. Ann Neurol (2003) 2.06
SLC30A8 nonsynonymous variant is associated with recovery following exercise and skeletal muscle size and strength. Diabetes (2013) 2.05
Calorie-related rapid onset of alveolar loss, regeneration, and changes in mouse lung gene expression. Am J Physiol Lung Cell Mol Physiol (2003) 2.04
Secreted proteome profiling in human RPE cell cultures derived from donors with age related macular degeneration and age matched healthy donors. J Proteome Res (2006) 2.04
Deacetylase inhibitors increase muscle cell size by promoting myoblast recruitment and fusion through induction of follistatin. Dev Cell (2004) 2.01
Interactively optimizing signal-to-noise ratios in expression profiling: project-specific algorithm selection and detection p-value weighting in Affymetrix microarrays. Bioinformatics (2004) 1.98
Variability in muscle size and strength gain after unilateral resistance training. Med Sci Sports Exerc (2005) 1.95
Diversity of mechanism-based pharmacodynamic models. Drug Metab Dispos (2003) 1.93
ACE ID genotype and the muscle strength and size response to unilateral resistance training. Med Sci Sports Exerc (2006) 1.86
Loss of emerin at the nuclear envelope disrupts the Rb1/E2F and MyoD pathways during muscle regeneration. Hum Mol Genet (2006) 1.85
Gene expression profiling in DQA1*0501+ children with untreated dermatomyositis: a novel model of pathogenesis. J Immunol (2002) 1.83
Tissue-specific alternative splicing of TCF7L2. Hum Mol Genet (2009) 1.80
The RNA helicases p68/p72 and the noncoding RNA SRA are coregulators of MyoD and skeletal muscle differentiation. Dev Cell (2006) 1.78
Constitutive activation of MAPK cascade in acute quadriplegic myopathy. Ann Neurol (2004) 1.77
Modeling of corticosteroid pharmacogenomics in rat liver using gene microarrays. J Pharmacol Exp Ther (2003) 1.71
GRB14, GPD1, and GDF8 as potential network collaborators in weight loss-induced improvements in insulin action in human skeletal muscle. Physiol Genomics (2006) 1.67
Dysferlin deficiency enhances monocyte phagocytosis: a model for the inflammatory onset of limb-girdle muscular dystrophy 2B. Am J Pathol (2008) 1.65
ACTN3 genotype is associated with increases in muscle strength in response to resistance training in women. J Appl Physiol (1985) (2005) 1.57
Embryonic myogenesis pathways in muscle regeneration. Dev Dyn (2004) 1.57
Differential dependency network analysis to identify condition-specific topological changes in biological networks. Bioinformatics (2008) 1.56
Microtubules underlie dysfunction in duchenne muscular dystrophy. Sci Signal (2012) 1.54
Probe set algorithms: is there a rational best bet? BMC Bioinformatics (2006) 1.53
Dystrophin-deficient cardiomyopathy in mouse: expression of Nox4 and Lox are associated with fibrosis and altered functional parameters in the heart. Neuromuscul Disord (2008) 1.52
ACTN3 and MLCK genotype associations with exertional muscle damage. J Appl Physiol (1985) (2005) 1.52
Functional characteristics of dystrophic skeletal muscle: insights from animal models. J Appl Physiol (1985) (2002) 1.50
Slug is a novel downstream target of MyoD. Temporal profiling in muscle regeneration. J Biol Chem (2002) 1.50
Functional polymorphisms associated with human muscle size and strength. Med Sci Sports Exerc (2004) 1.49
The cooperative international neuromuscular research group Duchenne natural history study--a longitudinal investigation in the era of glucocorticoid therapy: design of protocol and the methods used. Muscle Nerve (2013) 1.48
Pharmacokinetic and pharmacodynamic modeling of recombinant human erythropoietin after single and multiple doses in healthy volunteers. J Clin Pharmacol (2004) 1.45
Attenuation of colistin bactericidal activity by high inoculum of Pseudomonas aeruginosa characterized by a new mechanism-based population pharmacodynamic model. Antimicrob Agents Chemother (2010) 1.44
Pharmacokinetic/pharmacodynamic modelling in diabetes mellitus. Clin Pharmacokinet (2008) 1.44
Proteomics and systems biology in exercise and sport sciences research. Exerc Sport Sci Rev (2007) 1.43
Inflammasome up-regulation and activation in dysferlin-deficient skeletal muscle. Am J Pathol (2010) 1.41
Patterns of global gene expression in rat skeletal muscle during unloading and low-intensity ambulatory activity. Physiol Genomics (2003) 1.41
Fifth-generation model for corticosteroid pharmacodynamics: application to steady-state receptor down-regulation and enzyme induction patterns during seven-day continuous infusion of methylprednisolone in rats. J Pharmacokinet Pharmacodyn (2002) 1.40
The PEPR GeneChip data warehouse, and implementation of a dynamic time series query tool (SGQT) with graphical interface. Nucleic Acids Res (2004) 1.40
Rare missense and synonymous variants in UBE1 are associated with X-linked infantile spinal muscular atrophy. Am J Hum Genet (2008) 1.39
A web-accessible complete transcriptome of normal human and DMD muscle. Neuromuscul Disord (2002) 1.38
Pharmacodynamics and pharmacogenomics of methylprednisolone during 7-day infusions in rats. J Pharmacol Exp Ther (2002) 1.36
Physiologically based pharmacokinetic modeling of FTY720 (2-amino-2[2-(-4-octylphenyl)ethyl]propane-1,3-diol hydrochloride) in rats after oral and intravenous doses. Drug Metab Dispos (2006) 1.33
Bodywide skipping of exons 45-55 in dystrophic mdx52 mice by systemic antisense delivery. Proc Natl Acad Sci U S A (2012) 1.32
Receptor-mediated pharmacokinetics and pharmacodynamics of interferon-beta1a in monkeys. J Pharmacol Exp Ther (2003) 1.31
Skipping toward personalized molecular medicine. N Engl J Med (2007) 1.30
Response of rat muscle to acute resistance exercise defined by transcriptional and translational profiling. J Physiol (2002) 1.29
Integrated DNA, cDNA, and protein studies in Becker muscular dystrophy show high exception to the reading frame rule. Hum Mutat (2008) 1.29
Losartan decreases cardiac muscle fibrosis and improves cardiac function in dystrophin-deficient mdx mice. J Cardiovasc Pharmacol Ther (2011) 1.28
Canine models of Duchenne muscular dystrophy and their use in therapeutic strategies. Mamm Genome (2012) 1.28
Fgfr4 is required for effective muscle regeneration in vivo. Delineation of a MyoD-Tead2-Fgfr4 transcriptional pathway. J Biol Chem (2005) 1.27
Development and qualification of a pharmacodynamic model for the pronounced inoculum effect of ceftazidime against Pseudomonas aeruginosa. Antimicrob Agents Chemother (2008) 1.26
VBP15, a novel anti-inflammatory and membrane-stabilizer, improves muscular dystrophy without side effects. EMBO Mol Med (2013) 1.22
Balancing muscle hypertrophy and atrophy. Nat Med (2004) 1.22
Novel CLCN1 mutations with unique clinical and electrophysiological consequences. Brain (2002) 1.22
A randomized clinical trial to assess the effect of statins on skeletal muscle function and performance: rationale and study design. Prev Cardiol (2010) 1.21
In vivo and in vitro characterization of novel neuronal plasticity factors identified following spinal cord injury. J Biol Chem (2004) 1.20
Pharmacodynamic models for agents that alter production of natural cells with various distributions of lifespans. J Pharmacokinet Pharmacodyn (2006) 1.20
Olfactory biopsies demonstrate a defect in neuronal development in Rett's syndrome. Ann Neurol (2003) 1.19
Gene expression profiling of experimental traumatic spinal cord injury as a function of distance from impact site and injury severity. Physiol Genomics (2005) 1.19
An analysis of DNA methylation in human adipose tissue reveals differential modification of obesity genes before and after gastric bypass and weight loss. Genome Biol (2015) 1.19
Proteome analysis of skeletal muscle from obese and morbidly obese women. Diabetes (2005) 1.18
Gene expression analysis of hepatic roles in cause and development of diabetes in Goto-Kakizaki rats. J Endocrinol (2008) 1.18
In vivo filtering of in vitro expression data reveals MyoD targets. C R Biol (2004) 1.18
Expression profiling reveals metabolic and structural components of extraocular muscles. Physiol Genomics (2002) 1.17
Molecular responses of human muscle to eccentric exercise. J Appl Physiol (1985) (2003) 1.17
Scaling pharmacodynamics from in vitro and preclinical animal studies to humans. Drug Metab Pharmacokinet (2009) 1.17
Importance of SPP1 genotype as a covariate in clinical trials in Duchenne muscular dystrophy. Neurology (2012) 1.17
Direct analysis of lipids and small metabolites in mouse brain tissue by AP IR-MALDI and reactive LAESI mass spectrometry. Analyst (2010) 1.17
Gene arrays and temporal patterns of drug response: corticosteroid effects on rat liver. Funct Integr Genomics (2003) 1.16
Modeling corticosteroid effects in a rat model of rheumatoid arthritis I: mechanistic disease progression model for the time course of collagen-induced arthritis in Lewis rats. J Pharmacol Exp Ther (2008) 1.16
Pharmacokinetic and pharmacodynamic modeling of recombinant human erythropoietin after multiple subcutaneous doses in healthy subjects. Eur J Pharm Sci (2005) 1.16
Dose equivalency evaluation of major corticosteroids: pharmacokinetics and cell trafficking and cortisol dynamics. J Clin Pharmacol (2003) 1.16
Skeletal muscle dictates the fibrinolytic state after exercise training in overweight men with characteristics of metabolic syndrome. J Physiol (2003) 1.15
Expression of two temporally distinct microglia-related gene clusters after spinal cord injury. Glia (2006) 1.14
Corticosteroid-regulated genes in rat kidney: mining time series array data. Am J Physiol Endocrinol Metab (2005) 1.14
Dysferlin deficiency shows compensatory induction of Rab27A/Slp2a that may contribute to inflammatory onset. Am J Pathol (2008) 1.12
Pharmacogenomic responses of rat liver to methylprednisolone: an approach to mining a rich microarray time series. AAPS J (2005) 1.11
A renaissance for antisense oligonucleotide drugs in neurology: exon skipping breaks new ground. Arch Neurol (2009) 1.11
Optimized multilayer perceptrons for molecular classification and diagnosis using genomic data. Bioinformatics (2006) 1.11
Modeling circadian rhythms of glucocorticoid receptor and glutamine synthetase expression in rat skeletal muscle. Pharm Res (2006) 1.10
Microarray analysis of the temporal response of skeletal muscle to methylprednisolone: comparative analysis of two dosing regimens. Physiol Genomics (2007) 1.10
Glucocorticoid-treated mice are an inappropriate positive control for long-term preclinical studies in the mdx mouse. PLoS One (2012) 1.10
Circadian rhythms in gene expression: Relationship to physiology, disease, drug disposition and drug action. Adv Drug Deliv Rev (2010) 1.10